Rich Purcell, Senior VP of Research & Drug Development at Generex Biotechnology, discusses the NuGenerex MSO (managed services organization) model, areas of healthcare where strategic improvements can make a significant impact, gaps within traditional MSOs and specialties where new models can work best, and how drug discovery and development can be accelerated with revenue-generating business models.
Mr. Purcell has served as our Senior Vice-President of Research & Drug Development since January 2017. Since 2005, Mr. Purcell has managed a consulting practice, DNA Healthlink, Inc. advising emerging biopharmaceutical and technology companies on new business strategy, operations management, and clinical development of novel compounds. Since January 2017, he has served as the Senior Vice President of Research and Drug Development for Generex, active in strategic planning, business development, clinical operations, R&D, and M&A. Through DNA Healthlink, Mr. Purcell has been the SVP of R&D for RespireRx Pharmaceuticals since 2014. From 2011 to 2017, Mr. Purcell was the President and founder of a Healthcare IT startup, IntelliSanté. Mr. Purcell graduated with a degree in Biochemical Sciences from Princeton University, and attended Rutgers Graduate School of Management majoring in marketing and finance. He is also an Adjunct Professor of Biology at Monmouth University.
Rich graduated with a degree in Biochemical Sciences from Princeton University, and attended Rutgers Graduate School of Management majoring in marketing and finance. He is a member of NJTC, HIMSS, the Patient-Centered Primary Care Collaborative, the Drug Information Association and the Licensing Executives Society. He is also an Adjunct Professor of Biology at Monmouth University where he developed and teaches The Business of Biotechnology.